Premium
Partial Opioids: Medications for the Treatment of Pain and Drug Abuse
Author(s) -
BIDLACK JEAN M.,
McLAUGHLIN JAY P.,
WENTLAND MARK P.
Publication year - 2000
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2000.tb06672.x
Subject(s) - pentazocine , analgesic , agonist , partial agonist , pharmacology , κ opioid receptor , opioid , drug , kappa , chemistry , receptor , medicine , linguistics , philosophy
A bstract : Pentazocine and cyclazocine are two benzomorphans that were synthesized by the late Sydney Archer in 1962. These benzomorphans were synthesized as part of an effort to develop analgesics with little or no abuse potential. Pentazocine is used as an analgesic, often in individuals who have sever pain or in those who have drug‐abuse problems. Cyclazocine is a low‐liability analgesic and potential therapeutic for the treatment of drug abuse. The risk of drug dependence is lower with the benzomorphans, which usually act as partial agonists at the μ opioid receptor and as κ agonists. In an attempt to synthesize analogs of cyclazocine with increased bioavailability and varying κ agonist and partial μ agonist properties, a series of 8‐amino derivatives of cyclazocine were synthesized. These compounds were characterized in radioligand binding assays for their affinity and selectivity for the μ, δ, and κ opioid receptors. Mouse antinociceptive tests were used to characterize the agonist and antagonist properties of each compound at the μ, δ and κ receptors.